Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Fruquintinib plus paclitaxel could be a second-line treatment option for patients with gastric or gastroesophageal junction cancer, according to researchers. Fruquintinib plus paclitaxel could be a second-line treatment option for patients with gastric or GEJ cancer, according to researchers.
Fruquintinib plus paclitaxel could be a second-line treatment option for patients with gastric or gastroesophageal junction cancer, according to researchers. Fruquintinib plus paclitaxel could be a second-line treatment option for patients with gastric or GEJ cancer, according to researchers.
HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Fruquintinib/paclitaxel significantly improved PFS but not OS vs paclitaxel alone in the second-line treatment in patients with advanced gastric cancer.